HIMS showcases outstanding financial strength. With just $63 million in debt against a market value of $13 billion, the ...

Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (NYSE: HIMS) may finally be ...

Hims & Hers Health has seen massive success, aided by the growing use of GLP-1 drugs. Click here to find out why I downgrade ...

The direct-to-consumer telehealth company said the workforce reduction is unrelated to its weight-loss drug sector.

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Hims & Hers Health is betting that the cash ... Sustainabilitycategory· June 9, 2025 Activist hedge fund Parvus builds stake in Novo Nordisk, FT reports Activist hedge fund Parvus Asset ...

The cash-based acquisition – the financial terms of which are not being disclosed – will expand Hims & Hers' presence in the ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Tuesday, online health and wellness company Hims & Hers announced its intent to acquire European digital healthcare provider ...

In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199. 1 The offer is running through June 30, 2025. Following that, users ...